Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018128486) ANTI-CEACAM6 CHIMERIC ANTIGEN RECEPTOR SPECIFICALLY BINDING TO CEACAM6
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/128486 International Application No.: PCT/KR2018/000311
Publication Date: 12.07.2018 International Filing Date: 05.01.2018
IPC:
C07K 16/28 (2006.01) ,C07K 14/705 (2006.01) ,C07K 14/725 (2006.01) ,C12N 5/0783 (2010.01) ,A61K 35/17
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
725
T-cell receptors
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07
Animal cells or tissues
071
Vertebrate cells or tissues, e.g. human cells or tissues
078
Cells from blood or from the immune system
0783
T cells; NK cells; Progenitors of T or NK cells
[IPC code unknown for A61K 35/17]
Applicants:
한국생명공학연구원 KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY [KR/KR]; 대전시 유성구 과학로 125 125, Gwahak-ro Yuseong-gu Daejeon 34141, KR
다이노나(주) DINONA INC. [KR/KR]; 서울시 송파구 올림픽로43길 88, 11층 11th Fl., 88, Olympic-ro 43-gil Songpa-gu Seoul 05505, KR
Inventors:
최인표 CHOI, In Pyo; KR
김태돈 KIM, Tae-Don; KR
서희윤 SEO, Hui Yun; KR
이수연 LEE, Sooyun; KR
홍권표 HONG, Kwon Pyo; KR
Agent:
제일특허법인(유) FIRSTLAW P.C.; 서울시 서초구 마방로 60 60 Mabang-Ro Seocho-Ku, Seoul 06775, KR
제일특허법인(유) FIRSTLAW P.C.; 서울시 서초구 마방로 60 60 Mabang-Ro Seocho-Ku, Seoul 06775, KR
Priority Data:
10-2017-000196305.01.2017KR
Title (EN) ANTI-CEACAM6 CHIMERIC ANTIGEN RECEPTOR SPECIFICALLY BINDING TO CEACAM6
(FR) RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE ANTI-CEACAM6 SE LIANT DE MANIÈRE SPÉCIFIQUE À CEACAM6
(KO) CEACAM6에 특이적으로 결합하는 항-CEACAM6 키메릭 항원 수용체
Abstract:
(EN) The present invention relates to an anti-CEACAM6 chimeric antigen receptor (CAR) specifically binding to CEACAM6, and a cell therapeutic agent comprising same. The chimeric antigen receptor according to the present invention is characterized by specifically binding to CEACAM6 and can be a useful target for a targeted anticancer agent. Accordingly, the chimeric antigen receptor according to the present invention can induce immunocytes to move effectively to tumor tissue and be usefully employed in a gene and cell therapy exhibiting highly efficient anticancer effects.
(FR) La présente invention concerne un récepteur antigénique chimérique (CAR) anti-CEACAM6 se liant de manière spécifique à CEACAM6, et un agent thérapeutique cellulaire le comprenant. Le récepteur antigénique chimérique selon la présente invention est caractérisé en ce qu'il se lie de manière spécifique à CEACAM6 et peut être une cible utile pour un agent anticancéreux ciblé. Le récepteur récepteur antigénique chimérique selon la présente invention peut induire des immunocytes pour se déplacer efficacement vers un tissu tumoral et être utilement employé dans un gène et une thérapie cellulaire présentant des effets anticancéreux hautement efficaces.
(KO) 본 발명은 CEACAM6에 특이적으로 결합하는 항-CEACAM6 키메릭 항원 수용체 (CAR) 및 이를 포함하는 세포 치료제에 관한 것이다. 본 발명에 따른 키메릭 항원 수용체는 CEACAM6에 특이적으로 결합하는 것을 특징으로 하며, 표적 항암제에 유용한 타깃이 될 수 있다. 따라서 본 발명에 따른 키메릭 항원 수용체는 종양 조직에 효과적으로 면역세포가 이동하도록 유도할 수 있고, 효율 높은 항암 효과를 나타내는 유전자 세포 치료법에 유용하게 이용될 수 있다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)